
UB026
TargetsATR x mTOR
IndicationsMalignant melanoma; Oesophageal cancer; Colorectal cancer
ClinicalCN - I
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- **Market Entry Timing**: Targeting the patent expiry (LOE) window of the originator in key markets, positioning as a high-potential 'First Wave Generic' project, utilizing the NewCo structure for flexible commercial partnerships to capture early market share.
- **Ultimate Cost Competitiveness**: Leveraging China's strong upstream chemical infrastructure and API+FDF vertical integration to offer highly competitive supply prices, meeting the urgent cost-containment needs of global payers.
- **International Compliance Standards**: Emphasizing that product development follows ICH guidelines, with CMC data packages and quality systems ready for registration (ANDA/MA) in regulated markets (US/EU), minimizing regulatory risks for overseas clients.
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →